Karyopharm Therapeutics | KPTI - Operating Profit


Karyopharm Therapeutics reported $-26.76M in Operating Profit for its fiscal quarter ending in March of 2026.





Operating Profit Change Date
AbbVie USD 6.72B 1.99B Jun/2026
Abbott USD 2.13B 281M Jun/2026
Amgen USD 4.61B 777M Jun/2026
AstraZeneca USD 3.16B 3.95B Jun/2026
BioCryst Pharmaceuticals USD 98.46M 161.92M Jun/2026
Bristol-Myers Squibb USD 299M 3.07B Jun/2026
Eli Lilly USD 12.46B 2.68B Jun/2026
Enanta Pharmaceuticals USD -23.54M 98.15M Dec/2024
GlaxoSmithKline GBP 2.6B 312M Jun/2026
Incyte USD 700.4M 376.22M Jun/2026
J&J USD 6.47B 1B Sep/2026
Karyopharm Therapeutics USD -26.76M 8.92M Mar/2026
MacroGenics USD -33.44M 21.34M Mar/2026
Merck USD 840M 2.72B Jun/2026
Nektar Therapeutics USD -38.26M 19.17M Mar/2026
Novartis USD 4.75B 515M Jun/2026
Novartis USD 4.24B 171M Mar/2026
Pfizer USD 667M 4.32B Jun/2026
Regeneron Pharmaceuticals USD 1.42B 675.7M Jun/2026
Roche Holding CHF 11.46B 1.91B Jun/2026
Sangamo BioSciences USD -33.51M 12.77M Jun/2024
Takeda JPY 201.42B 215.04B Jun/2026
Tectonic Therapeutic USD -27.3M 5.78M Mar/2026
TG Therapeutics USD 21.67M 13.12M Jun/2026
Ultragenyx Pharmaceutical USD -75M 141M Jun/2026
Xencor USD -36.6M 41.26M Jun/2026